ClinicalTrials.gg
RecruitingNCT07844057FIRE-12Updated Nov 16, 2026

First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma

A Phase 2 interventional study of mFOLFIRINOX versus FOLFOX chemotherapy in Small-bowel Adenocarcinoma, Metastatic Disease and Chemotherapy Effect, sponsored by Annika Kurreck. Recruiting at 16 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Annika Kurreck · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 323 studies in Neoplasm Metastasis with a site in Germany — 52 open to participants now, 91 under way, 36 of them phase 3. Neoplasm Metastasis · Germany.

Planned enrollment
207th of 292
86 · median 214
Started
2026
with 7 others
Phase 2
81 of 323
7 open now
Primary completion
2029-10
later than 77 of 90 live
Registered
323rd of 323
by date

Among the 323 studies in Neoplasm Metastasis with a site in Germany, this one is the 207th largest by planned enrollment of the 292 interventional ones that give a count, is one of 8 that started in 2026, is one of 81 in phase 2, reaches primary completion later than 77 of the 90 other live ones, and was the 323rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

52 of the 323 studies in Neoplasm Metastasis with a site in Germany are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Neoplasm Metastasis with a site in Germany, or all of them as a file.
02

Study summary

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

Read the detailed description

Background:

Small bowel adenocarcinoma (SBA) is rare malignant disease accounting for less than 5% of all gastrointestinal tumors [1]. At time of first diagnosis about 40% of patients have distant metastases and more than half of the patients with initially resected SBA and lymph node invasion will experience metastatic recurrence [2]. Tumor phenotype characterization indicates that SBA molecular alterations are similar to adenocarcinoma of the colorectum [3, 4].

Palliative chemotherapy in SBA was mainly evaluated within retrospective studies. Fluoropyrimidines in combination with platinum derivates, especially oxaliplatin, appear to be the most efficient treatment regimen [5, 6]. The median progression-free survival (PFS) ranges from 6.9 to 8.7 months. Two prospective phase II studies evaluated the efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) or the oral prodrug capecitabine reporting an objective response rate (ORR) of approximately 50% with a median PFS of 7.8 and 11.3 months, and a median overall survival (OS) of 15.2 and 20.4 months, respectively [7, 8]. Indeed, FOLFOX regimen (5-FU+ oxaliplatin) represents the standard of care chemotherapy used worldwide [9, 10]. Treatment with anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody was evaluate in a pilot study that report no signal of efficacy [11]. The anti-Vascular Endothelial Growth Factor (VEGF) monoclonal antibody Bevacizumab was also evaluated in a phase II trial in combination with capecitabine and oxaliplatin [12] with comparable results observed in a previous phase II trial investigating the same chemotherapy regimen without bevacizumab [7, 8]. Moreover, a registry study suggests that there is no benefit of adding bevacizumab to chemotherapy in first-line treatment of SBA [13]. Thus, it seems that FOLFOX or CAPOX (capecitabine+ oxaliplatin) without the addition of a monoclonal antibody represents one of the best therapeutic options in first-line treatment of SBA.

In metastatic colorectal adenocarcinoma the triplet regimen consisting of 5-FU, folinic acid, oxaliplatin, and irinotecan demonstrated an improved efficacy compared to doublet regimen depending on molecular subtype [14]. The median PFS was better in patients receiving triplet regimen compared to doublet chemotherapy (9.8 months versus 6.9 months). Moreover, in metastatic pancreatic adenocarcinoma triplet chemotherapy with FOLFIRINOX represents the current standard of care due to a significantly improved PFS and OS compared to former standard treatment with gemcitabine [15].

In SBA, a phase II trial including a small number of patients evaluated the triplet chemotherapy with capecitabine, irinotecan, and oxaliplatin. The authors reported a moderate ORR of 37.5%, a median PFS of 8.9 months, and a median OS of 13.4 months [16]. The moderate efficacy might be a result of the unusual choice of capecitabine instead of infusional 5-FU as component of the triplet regimen.

The superiority of triplet chemotherapy in molecularly selected metastatic colorectal cancer and metastatic pancreatic adenocarcinoma advocate an evaluation in first-line setting of SBA.

The optimal sequence of currently available treatment regimens in SBA is under debate. There is small evidence for the use of irinotecan-based regimens, such as FOLFIRI [17], taxane-based regimens [18], or molecularly targeted therapy [19] in subsequent treatment lines.

In the past decades, little progress has been made in the treatment of SBA with regard to survival parameters [20] in contrast to other entities, such as mCRC. The lack of prospective clinical trials resulting in a lack of evidence-based treatment recommendations can be identified as one of the main reasons for missing improvements in the treatment of SBA.

Due to the rarity of SBA, it is not feasible to conduct a phase III study of adequate duration. Therefore, a randomized phase II study will be conducted to not only validate the efficacy signal of triplet chemotherapy with mFOLFIRINOX in the first-line treatment of SBA, but also to generate evidence for national therapy guidelines and to improve the medical care of patients with SBA.

Objectives:

Primary objective

  • To compare the efficacy of doublet chemotherapy with FOLFOX and triplet chemotherapy with mFOLFIRINOX in first-line treatment of SBA Secondary objectives
  • To compare efficacy, safety and patient patient-reported quality of life (QoL) of doublet chemotherapy with FOLFOX and triplet chemotherapy with mFOLFIRINOX in first-line treatment of SBA
  • To assess efficacy of subsequent antitumor treatment Exploratory objectives
  • To identify predictive and prognostic factors and to characterize patient subgroups in order to correlate their genetic and molecular tumor characteristics with clinical efficacy and toxicity using tumor specimen and blood-based biomarker candidates
  • To identify the optimal sequence of antitumoral treatment in irresectable or metastatic SBA.

Endpoints:

Primary study endpoint Progression-free survival (PFS)-, defined as time from the date of randomization to the date of first radiological disease progression according to RECIST version 1.1 or the date of death from any cause.

Secondary study endpoints Efficacy

  • Overall survival (OS)
  • Objective response rate (ORR)
  • Depth of response (DpR)

Safety

  • Type, incidence, severity, and causal relationship to active chemotherapystudy treatment of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 56.0) Quality of life
  • Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L Exploratory endpoints
  • Efficacy endpoints according to circulating tumor DNA (ctDNA) at baseline and at pre-defined time points during study treatment
  • Effficacy endpoints according to molecular alterations
  • Effficacy endpoints according to circulating tumor DNA (ctDNA)
  • Treatments (including regimen, duration, efficacy) beyond study treatment
  • PFS of subsequent treatment line (PFS2, 2nd line PFS)

Trial design:

This is an open-label, randomized, controlled, multicenter, phase II trial with two parallel arms. Patients with locally advanced irresectable or metastatic small bowel adenocarcinoma are randomized in a 1:1 fashion to investigate the efficacy, patient -reported quality of life and safety of triplet chemotherapy with mFOLFIRINOX (arm A) versus doublet chemotherapy with FOLFOX (arm B).

During the randomization process stratification will be performed according to the following parameters:

1. Locally advanced versus synchronous metastatic versus metachronous metastatic metastatic SBASBA 2. ECOG performance status 0-1 versus 2

Systemic treatment in both arms is performed biweekly until disease progression, occurence of unacceptable toxicity, at the patient's request, at discretion of the investigator, whatever occurs first.

Patients will be followed up with regard to disease progression, survival and if applicable subsequent treatments until death or for at least 4 years after randomization, whichever date occurs first.

Inclusion criteria:

Participants Patients are eligible to be included in the trial only if all of the following criteria apply at time of enrollment:

  1. Patient's signed informed consent.
  2. Patient's age ≥18 years at the time of signing the informed consent.
  3. Histologically confirmed small bowel adenocarcinoma.
  4. Microsatellite stable tumor or proficient mismatch repair status of the SBA (immunohistochemistry and polymerase chain reaction are both allowed for characterization)
  5. Predicted locally advanced irresectable by the local study team or presenting with distant metastases.
  6. Patient did not receive antitumor treatment for locally advanced irresetable or metastatic disease.
  7. Measurable lesion according to RECIST 1.1.
  8. ECOG performance status 0-2. In case of patient's age >70 years, ECOG has to be 0 or 1 at randomization
  9. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:

    • Absolute neutrophil count 1.5 x 109/L (1500/µL)
    • Hemoglobin ≥ 80 g/L (8 g/dL) with or without blood transfusion
    • Platelet count ≥ 100 x109/L (100000/µL) without transfusion
    • Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) ≤ 2.5 × ULN; if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN
    • Aspartate aminotransferase (AST/GOT) ≤ 3.0 × ULN.
    • Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL/min or serum creatinine≤ 1.5x ULN
  10. Patients without anticoagulation need to present with an INR\< 1.5x ULN and aPTT \<1.5x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
  11. Proficient fluorouracil metabolism as defined:

    - Prior treatment with 5-FU or capecitabine without unusal toxicity or

    • If tested, normal DPD deficiency test according to the standard of the study site or
    • If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%
  12. For women of childbearing potential (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of study treatment.

A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

For men: Wwith female partners of childbearing potential,: men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.

Men Wwith pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo.

Exclusion criteria:

Patients are excluded from this trial if any of the following criteria apply at time of enrollment:

  1. Adenocarcinoma of the ampulla of Vateri
  2. Ileus or directly imminent ileus as assessed by the local study team. Patients with treated and resolved ileus are allowed into the trial.
  3. Previous chemotherapy for metastatic or irresectable disease.

3. Adjuvant chemotherapy completed less than 6 months ago 4. New York Heart Association Class III or greater heart failure by clinical judgement.

5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.

6. Unstable angina pectoris. 7. Unstable cardiac arrhythmia >grade 2 NCI CTCAE despite anti-arrhythmic therapy.

8. Ongoing toxicities >grade 2 NCI CTCAE, in particular peripheral neuropathy. 9. Active uncontrolled infection by investigator's perspective. 10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.

11. Known hypersensitivity to 5-FU, leucovorin, capecitabine, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding SmPC.

12. Recent or concomitant treatment with brivudine. 13. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 65.0 (see appendix 2)).

14. Simultaneous application of Johannis herbs preparations. 15. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency. 16. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization that may interfere with systemic therapy as judged by the investigator.

17. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.

18. Medical history of malignant disease other than small bowel adenocarcinomaSBA with the following exceptions: 18.1. patients who have been disease-free for at least three years before randomization 18.2. patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer 18.3. patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 80% and does not require active therapy at randomization 18.4.18.3. 19. Known alcohol or drug abuse. 20. Pregnant or breastfeeding females. 21. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.

22. Patients dependentd on Sponsor, investigator or study site. 23. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

24. Limited legal capacity. 25. Inability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.

Treatment, dosage, and administration:

Treatment arm A: mFOLFIRINOX every two weeks

  • oxaliplatin 85 mg/m² 2 hours intravenously
  • irinotecan 150 mg/m² 60-90 minutes intravenously
  • leucovorin 400 mg/m² 2 hours intravenously
  • 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion Treatment arm B: FOLFOX every two weeks
  • oxaliplatin 85 mg/m² 2 hours intravenously
  • leucovorin 400 mg/m² 2 hours intravenously
  • 5-fluorouracil 400 mg/m² intravenous bolus injection
  • 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion

Dose de-escalations and dose modifications are allowed per institutional standard as investigators decision.

Systemic treatment in both arms will be continued until disease progression, occurence of unacceptable toxicity, at the patient's request, at discretion of the investigator, whatever occurs first.

Translational research:

The translational research program consists of the following steps but might be modified or expanded taking latest scientific data into account :

  1. Characterization of tumor specimens for DNA mutations and RNA expressions (for example panel NGS and mRNA expression analysis)
  2. Longitudinal assessments of tumor markers and circulating tumor DNA (according to initial tumor characteristics), assessments should include the baseline, 3 months, and 6 months time points (and optional further time points as long as no disease progression occurred as scheduled above).
  3. Characterization of tumor specimen obtained after relapse of disease during or after study (if occurring and available) for DNA mutations and RNA expressions.

This paired sample collection including specimen and the longitudinal assessment of circulating tumor DNA will be performed in order to inform about early detection of disease progression (potentially prior to radiographic correlate), patterns of disease progression and molecular background of disease progression (tumor evolution, secondary mutations, expressions).

Statistical considerations:

With a power of 80%, a 2-sided alpha of 0,1, a total of 73 events are need to be observed in order to detect a difference in progression-free survival of a hazard ratio of 0.557- favoring the experimental treatment vs. control (Schoenfeld formula) in a 1:1 randomized trial, assuming a PFS 6.1 months for the control arm and 10.9 months for the experimental arm. Assuming an accrual time of 36 months and a follow-up time of 24 months for the primary endpoint, a drop-out/censoring rate of 10% after randomization , a total of 112 patients (56 per group) in the respective arms, rounded to receive integers and maintain the allocation ratio) is expected to yield the required number of events if the accrual rate is constant. From the available data mentioned above, it was assumed that the event rate follows an exponential distribution without reaching a relevant plateau. The computation was done using the software R Version 3.5.1 and the package Rpact.

PFS will be estimated by Kaplan-Meier-Curves and comparison of treatment arms will be performed by using a Cox-Regression with adjustment for the stratification factors (Locally advanced versus metastatic SBA; Synchronous versus metachronous metastases; ECOG performance status 0-1 versus 2), Hazard Ratio for the main factor treatment group with 90% Wald-Confidence intervals will be reported. Primary analysis will be performed on the FAS data set.

Duration and end of trial:

First patient in (FPI) to Last patient in (LPI): 36 months

Primary endpoint (PFS) after randomization: LPI+ 10 months (46 months total) Secondary endpoints: LPI+ 48 months (84 months total)

End of Study (EOS) Last visit of last patient (LVLP) Last patient in (LPI)+ 48 months (FPI+ 90 months in total)

03

Conditions studied

  • Small-bowel Adenocarcinoma
  • Metastatic Disease
  • Chemotherapy Effect

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible to be included in the trial only if all of the following criteria apply at time of enrollment:

  1. Patient's signed .
  2. Patient's age ≥18 years at the time of signing the informed consent.
  3. confirmed small bowel adenocarcinoma.
  4. Microsatellite stable tumor or proficient mismatch repair status of the SBA (immunohistochemistry and polymerase chain reaction are both allowed for characterization)
  5. Predicted locally advanced irresectable by the local study team or presenting with distant .
  6. Patient did not receive antitumor treatment for locally advanced irresetable or metastatic disease.
  7. according to 1.1.
  8. performance status 0-2. In case of patient's age >70 years, ECOG has to be 0 or 1 at randomization
  9. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:

    • 1.5 x 109/L (1500/µL)
    • ≥ 80 g/L (8 g/dL) with or without blood transfusion
    • count ≥ 100 x109/L (100000/µL) without transfusion
    • Total serum of ≤ 1.5 x (ULN)
    • (AST/GOT) and alanine aminotransferase (ALT/GPT) ≤ 2.5 × ULN; if liver function abnormalities are due to underlying liver metastasis, AST and ALT ≤ 5 × ULN
    • Calculated (GFR) according to formula or according to MDRD ≥ 50 mL/min or serum creatinine≤ 1.5x ULN
  10. Patients without anticoagulation need to present with an \< 1.5x ULN and aPTT \<1.5x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.
  11. Proficient fluorouracil metabolism as defined:

    • Prior treatment with 5-FU or capecitabine without unusal toxicity or
    • If tested, normal DPD deficiency test according to the standard of the study site or
    • If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%
  12. For women of (WOCBP): negative pregnancy test within 14 days before randomization and agreement to remain abstinent (refrain from heterosexual intercourse) or use methods with a failure rate of \< 1% per year during the treatment period and for at least 6 months after the last dose of study treatment.

A woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.

For men with female partners of childbearing potential: men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.

Men with pregnant female partners must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo.

Exclusion criteria

Exclusion Criteria:

Patients are excluded from this trial if any of the following criteria apply at time of enrollment:

  1. Adenocarcinoma of the ampulla of Vateri
  2. Ileus or directly imminent ileus as assessed by the local study team. Patients with treated and resolved ileus are allowed into the trial.
  3. Previous chemotherapy for or irresectable disease.
  4. Class III or greater heart failure by clinical judgement.
  5. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.
  6. Unstable angina pectoris.
  7. Unstable cardiac arrhythmia >grade 2 despite anti-arrhythmic therapy.
  8. Ongoing toxicities >grade 2 NCI CTCAE, in particular peripheral neuropathy.
  9. Active uncontrolled infection by investigator's perspective.
  10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture.
  11. Known to 5-FU, leucovorin, capecitabine, irinotecan or oxaliplatin or to any of the other listed in section 6.1 of the corresponding SmPC.
  12. Recent or concomitant treatment with brivudine.
  13. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to CTCAE version 6.0 (see appendix 2)).
  14. Simultaneous application of Johannis herbs preparations.
  15. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.
  16. Major surgical procedure, open , or significant traumatic injury within 21 days prior to randomization that may interfere with systemic therapy as judged by the investigator.
  17. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
  18. Medical history of malignant disease other than SBA with the following exceptions:

    18.1. patients who have been disease-free for at least three years before randomization 18.2. patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer 18.3. patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 80% and does not require active therapy at randomization

  19. Known alcohol or drug abuse.
  20. Pregnant or breastfeeding females.
  21. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.
  22. Patients dependent on Sponsor, investigator or study site.
  23. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  24. Limited legal capacity. Inability to undergo the medical follow-up of the trial for geographical, social or psychological reasons.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Other
    Treatment arm A: mFOLFIRINOX every two weeks

    * oxaliplatin 85 mg/m² 2 hours intravenously * irinotecan 150 mg/m² 60-90 minutes intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion

    Drug: mFOLFIRINOX versus FOLFOX chemotherapy

  • Other
    Treatment arm B: FOLFOX every two weeks

    * oxaliplatin 85 mg/m² 2 hours intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 400 mg/m² intravenous bolus injection * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion

    Drug: mFOLFIRINOX versus FOLFOX chemotherapy

Interventions

  • DrugmFOLFIRINOX versus FOLFOX chemotherapy

    Systemic treatment in both arms will be continued until disease progression, occurence of unacceptable toxicity, at the patient's request, at discretion of the investigator, whatever occurs first.

06

What researchers measure

Primary outcomes

  1. Median Progression-free survival (PFS)

    Progression-free survival (PFS)-, defined as time from the date of randomization to the date of first radiological disease progression according to RECIST version 1.1 or the date of death from any cause.

    Time frame: 84 months

Secondary outcomes

  1. Median Overall survival (OS)

    Overall survival (OS), is defined as the time from the date of randomisation to the date of death (from any cause). The date of the last contact known alive respectively date of the last tumor.assessment known progression-free.

    Time frame: 84 months

  2. Objective response rate (ORR)

    Objective respone rate (ORR), defined as rate of complete (CR) and partial responses (PR) during study treatment compared to baseline according to RECIST 1.1.

    Time frame: 84 months

  3. Patient Safety

    Type, incidence, severity, and causal relationship to study treatment of non-serious adverse events and serious adverse events (severity evaluated according to CTCAE version 6.0)

    Time frame: 84 months

  4. Quality of life (QoL)

    Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L

    Time frame: 84 months

  5. Depth of response (DpR),

    Depth of response (DpR), defined as change in percent from baseline to smallest tumor diameter (measurements according to RECIST 1.1 definition).

    Time frame: 84 months

07

Study locations

2 of 16 sites recruiting
  • Universitätsklinikum Augsburg
    Augsburg, 86156, Germany
    Not yet recruiting
    • Frank Jordan, Dr. · Contact
  • HELIOS Klinikum Bad Saarow
    Bad Saarow, 15526, Germany
    Not yet recruiting
    • Daniel Pink, Dr. · Contact
  • Charité Berlin - CVK
    Berlin, 13353, Germany
    Recruiting
    • Dominik P. Modest, Prof. Dr. · Contact
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
    Not yet recruiting
    • Börge Arndt, Dr. · Contact
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09116, Germany
    Not yet recruiting
    • Mathias Hänel, Prof. Dr. · Contact
  • Krankenhaus Nordwest GmbH- Institut für Klinisch-Onkologische Forschung
    Frankfurt, 60488, Germany
    Not yet recruiting
    • Thorsten O. Götze, Prof. Dr. · Contact
  • Marien Hospital Herne
    Herne, 44625, Germany
    Not yet recruiting
    • Viktor Rempel, Dr. · Contact
  • VK&K Studien GbR Landshut
    Landshut, 84036, Germany
    Not yet recruiting
    • Florian Kaiser, Dr. · Contact
  • Klinikum der LMU München - Medizinische Klinik und Poliklinik 3
    München, 81377, Germany
    Not yet recruiting
    • Julian Holch, Dr. · Contact
  • Rheinlandklinikum Lukaskrankenhaus Neuss
    Neuss, 41464, Germany
    Not yet recruiting
    • Ulf Reinhart, Dr. · Contact
  • Klinikum Oldenburg
    Oldenburg, 26133, Germany
    Not yet recruiting
    • Andrea Renzelmann, Dr. · Contact
  • Elblandklinikum Riesa
    Riesa, 01589, Germany
    Not yet recruiting
    • Jörg Schubert, Prof. Dr. · Contact
  • Universitätsmedizin Rostock - Departement für Innere Medizin
    Rostock, 18057, Germany
    Not yet recruiting
    • Hartmut Gläser, Dr. Dr. · Contact
  • Rostock Klinikum Südstadt
    Rostock, 18059, Germany
    Not yet recruiting
    • Beate Krammer-Steiner, Dr. · Contact
  • St. Josefs-Hospital Wiesbaden
    Wiesbaden, 65189, Germany
    Recruiting
    • Christoph Sarrazin, Prof. Dr. · Contact
  • Cellitinnen Krankenhaus St. Petrus Wuppertal
    Wuppertal, 42283, Germany
    Not yet recruiting
    • Matthias Sandmann, Dr. · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2029, 35 months after the start.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 35 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 28, 2026
StartActual
Oct 22, 2026
Primary completionEst.
Oct 1, 2029
CompletionEst.
Apr 1, 2034
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
16 sites changed recruiting status (14 now not yet recruiting, 2 now recruiting)
Show 16 sites
  • Universitätsklinikum Augsburg · Augsburg, Germanyno status→Not yet recruiting
  • HELIOS Klinikum Bad Saarow · Bad Saarow, Germanyno status→Not yet recruiting
  • Charité Berlin - CVK · Berlin, Germanyno status→Recruiting
  • Helios Klinikum Emil von Behring · Berlin, Germanyno status→Not yet recruiting
  • Klinikum Chemnitz gGmbH · Chemnitz, Germanyno status→Not yet recruiting
  • Krankenhaus Nordwest GmbH- Institut für Klinisch-Onkologische Forschung · Frankfurt, Germanyno status→Not yet recruiting
  • Marien Hospital Herne · Herne, Germanyno status→Not yet recruiting
  • VK&K Studien GbR Landshut · Landshut, Germanyno status→Not yet recruiting
  • Klinikum der LMU München - Medizinische Klinik und Poliklinik 3 · München, Germanyno status→Not yet recruiting
  • Rheinlandklinikum Lukaskrankenhaus Neuss · Neuss, Germanyno status→Not yet recruiting
  • Klinikum Oldenburg · Oldenburg, Germanyno status→Not yet recruiting
  • Elblandklinikum Riesa · Riesa, Germanyno status→Not yet recruiting
  • Universitätsmedizin Rostock - Departement für Innere Medizin · Rostock, Germanyno status→Not yet recruiting
  • Rostock Klinikum Südstadt · Rostock, Germanyno status→Not yet recruiting
  • St. Josefs-Hospital Wiesbaden · Wiesbaden, Germanyno status→Recruiting
  • Cellitinnen Krankenhaus St. Petrus Wuppertal · Wuppertal, Germanyno status→Not yet recruiting
Nov 16, 2026
Start date
Oct 1, 2026→Oct 22, 2026 (actual)
Nov 16, 2026
Secondary outcomes
1 added, 2 description edited
What changed in the outcomes
  • AddedDepth of response (DpR),Time frame: 84 months
  • DescriptionMedian Overall survival (OS): how it is measured was reworded
  • DescriptionObjective response rate (ORR): how it is measured was reworded
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Helios Klinikum Emil von Behring · Berlin, GermanyContact added (no phone or email listed)
Nov 16, 2026
Registered
First appeared on the registry
Sep 28, 2026
Show all 2 updates
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    16 sites changed recruiting status (14 now not yet recruiting, 2 now recruiting)
    Show 16 sites
    • Universitätsklinikum Augsburg · Augsburg, Germanyno status→Not yet recruiting
    • HELIOS Klinikum Bad Saarow · Bad Saarow, Germanyno status→Not yet recruiting
    • Charité Berlin - CVK · Berlin, Germanyno status→Recruiting
    • Helios Klinikum Emil von Behring · Berlin, Germanyno status→Not yet recruiting
    • Klinikum Chemnitz gGmbH · Chemnitz, Germanyno status→Not yet recruiting
    • Krankenhaus Nordwest GmbH- Institut für Klinisch-Onkologische Forschung · Frankfurt, Germanyno status→Not yet recruiting
    • Marien Hospital Herne · Herne, Germanyno status→Not yet recruiting
    • VK&K Studien GbR Landshut · Landshut, Germanyno status→Not yet recruiting
    • Klinikum der LMU München - Medizinische Klinik und Poliklinik 3 · München, Germanyno status→Not yet recruiting
    • Rheinlandklinikum Lukaskrankenhaus Neuss · Neuss, Germanyno status→Not yet recruiting
    • Klinikum Oldenburg · Oldenburg, Germanyno status→Not yet recruiting
    • Elblandklinikum Riesa · Riesa, Germanyno status→Not yet recruiting
    • Universitätsmedizin Rostock - Departement für Innere Medizin · Rostock, Germanyno status→Not yet recruiting
    • Rostock Klinikum Südstadt · Rostock, Germanyno status→Not yet recruiting
    • St. Josefs-Hospital Wiesbaden · Wiesbaden, Germanyno status→Recruiting
    • Cellitinnen Krankenhaus St. Petrus Wuppertal · Wuppertal, Germanyno status→Not yet recruiting
    Start date Oct 1, 2026→Oct 22, 2026 (now actual)
    Secondary outcomes 1 added, 2 description edited
    What changed in the outcomes
    • AddedDepth of response (DpR),Time frame: 84 months
    • DescriptionMedian Overall survival (OS): how it is measured was reworded
    • DescriptionObjective response rate (ORR): how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Helios Klinikum Emil von Behring · Berlin, GermanyContact added (no phone or email listed)
    + 1 other change: verification date
  2. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07844057
Lead sponsor
Annika Kurreck
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Annika Kurreck (PD Dr. med., Charite University, Berlin, Germany) — Sponsor-investigator
First posted
Sep 28, 2026
Start date
Oct 22, 2026
Primary completion
Oct 1, 2029 (estimated)
Completion
Apr 1, 2034 (estimated)
Last update
Nov 16, 2026

Study contacts

Aljoscha Joppe, Dr.
Contact
joppe.aljoscha@ikf-khnw.de
+49 (0) 69589978738
Inna Hoyer, Dr.
Contact
inna.hoyer@charite.de
+49 30450553727
Annika Kurreck, PD Dr.
principal investigator · Charité- Universitaetsmedizin Berlin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion